News

Oscar Health and other multiline insurers may benefit from diversification, digitalization and M&A trends despite pricing pressure and inflation.

In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $30.61, denoting a -1.48% move from the preceding trading day.

Better pricing, product redesigns and technological advancements are expected to aid Zacks Multiline Insurance industry players like OSCR, RDN, CNO, PLGO and HMN.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Oscar Health (OSCR) leverages a tech-driven platform and innovative insurance offerings to differentiate in the ACA marketplace. OSCR exhibits strong technical momentum and maintains a 100% “Buy” opinion from Barchart. Shares are up 106% over the past year. OSCR is gaining investor attention, trading near all-time highs, and is expected...

In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $31.2, indicating a +1.27% shift from the previous trading day.

In recent days, Oscar Health has drawn attention for strong revenue growth, expanding exposure to the Affordable Care Act market, and mixed analyst views on its valuation and profitability outlook. At the same time, a family trust linked to director Mario Schlosser sold and converted Class A and Class B shares under a pre-arranged trading plan, highlighting insider portfolio diversification rather than a shift in overall ownership exposure. Now we’ll examine how Oscar’s rapid revenue...

Oscar Health stock has logged a very large 3 year gain, yet recent valuation checks and analyst commentary suggest the shares may still be priced below what some investors expect for its growth profile. With the stock already reflecting strong momentum and mixed views from analysts, the question is whether the current valuation leaves enough room for further upside without stretching fundamentals. Oscar Health has returned about 277.2% over the past 3 years, which puts extra focus on whether...

Here is how Apple Hospitality REIT (APLE) and Oscar Health, Inc. (OSCR) have performed compared to their sector so far this year.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

The latest trading day saw Oscar Health, Inc. (OSCR) settling at $31.44, representing a -2.3% change from its previous close.

Baird said the outcomes from the final 2025 healthcare exchange risk adjustment transfers support Centene’s prior Q4 commentary and align directionally with Oscar’s comments at a June investor conference.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Oscar Health, Inc. (OSCR) closed at $28.52 in the latest trading session, marking a -3.16% move from the prior day.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how health insurance providers stocks fared in Q1, starting with Oscar Health (NYSE:OSCR).

Oscar Health, Inc. (OSCR) concluded the recent trading session at $29.16, signifying a -2.57% move from its prior day's close.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 5.2% gain for healthcare stocks has fallen short of the S&P 500’s 8.5% rise.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Investors are still underrating this insurance disrupter.

The latest trading day saw Oscar Health, Inc. (OSCR) settling at $28.26, representing a -2.25% change from its previous close.

Oscar Health (OSCR) has been back on investors’ radar after a sharp stock rally following its business update at the Goldman Sachs Healthcare Conference, where management reaffirmed full-year 2026 guidance and highlighted favorable utilization trends. See our latest analysis for Oscar Health. The stock’s rally around the Goldman Sachs Healthcare Conference and upbeat commentary on utilization trends come on top of very strong momentum, with a 90 day share price return of 118.52% and a 1 year...

Is OSCR a good stock to buy? We came across a bullish thesis on Oscar Health, Inc. on Deep Value Returns’s Substack. In this article, we will summarize the bulls’ thesis on OSCR. Oscar Health, Inc.’s share was trading at $27.22 as of June 9th. Oscar Health, Inc. operates as a healthcare technology company in the United […]

Capital continued to flow toward companies with visible execution and growth opportunities.

Oscar Health shares rally on a bullish Barclays’ research note. Here’s how high the investment firm believes OSCR stock could fly in 2026.

Barclays upgraded its rating of Oscar to overweight, a buy equivalent, and reiterated its overweight rating on Centene in a new research note.

Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls

Apple drew investor interest with a major AI update, Oscar Health reaffirmed its outlook, and Eli Lilly further strengthened its position in the weight-loss drug market.

Shares of health insurance company Oscar Health (NYSE:OSCR) jumped 10.8% in the afternoon session after the company provided a business update and reaffirmed its full-year 2026 guidance during a presentation at the Goldman Sachs Healthcare Conference.

Despite ACA market challenges and exits by Cigna and Aetna, Oscar sees competitor withdrawals as a potential opportunity for growth in 2027.

Oscar Health, Inc. recently amended and restated its employment agreement with co-founder Mario Schlosser as he moved from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO, effective June 1, 2026, while he continues to support the company’s artificial intelligence and digital health agenda and remains on the Board. At the same time, a major Wall Street firm upgraded its view on Oscar Health after Q1 2026 results exceeded expectations and reinforced...